[1] Schilsky RL, Michels DL, Kearbey AH, et al. Building a rapid learning health care system for oncology: the regulatory framework of CancerLinQ[J]. J Clin Oncol, 2014, 32(22): 2373-2379. DOI:10.1200/JCO.2014.56.2124.
[2]Helft M. Can big data cure cancer?[J]. Fortune, 2014, 170(2): 7074, 76, 78.
[3]Tomczak K, Czerwińska P, Wiznerowicz M. The cancer genome atlas (TCGA): an immeasurable source of knowledge[J]. Contemp Oncol (Pozn), 2015, 19(1A): A68-A77. DOI:10.5114/wo.2014.47136.
[4]Wilks C, Cline MS, Weiler E, et al. The cancer genomics hub (CGHub): overcoming cancer through the power of torrential data[J]. Database (Oxford), 2014, 2014: pii: bau093. DOI:10.1093/database/bau093.
[5]International Cancer Genome Consortium, Hudson TJ, Anderson W, et al. International network of cancer genome projects[J]. Nature, 2010, 464(7291): 993-998. DOI:10.1038/nature08987.
[6]Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes[J]. Science, 2013, 339(6127): 1546-1558. DOI:10.1126/science.1235122.
[7]Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene[J]. Science, 2009, 324(5924): 217. DOI:10.1126/science.1171202.
[8]Thirumurthi U, Shen J, Xia W, et al. MDM2mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer[J]. Sci Signal, 2014, 7(336): ra71. DOI:10.1126/scisignal.2005076.
[9]Taylor CR. From microscopy to whole slide digital images: a century and a half of image analysis[J]. Appl Immunohistochem Mol Morphol, 2011, 19(6): 491-493. DOI:10.1097/PAI.0b013e318229ffd6.
[10] Gu J, Taylor CR. Practicing pathology in the era of big data and personalized medicine[J]. Appl Immunohistochem Mol Morphol, 2014, 22(1): 1-9. DOI:10.1097/PAI.0000000000000022.
[11] Muzny DM, Bainbridge MN, Chang K, et al. Comprehensive molecular characterization of human colon and rectal cancer[J]. Nature, 2012, 487(747): 330-337. DOI:10.1038/nature11252.
[12] Kunz M. Genomic signatures for individualized treatment of malignant tumors[J]. Curr Drug Discov Technol, 2008, 5(1): 9-14.
[13] Greene CS, Tan J, Ung M, et al. Big data bioinformatics[J]. J Cell Physiol, 2014, 229(12): 1896-1900. DOI:10.1002/jcp.24662.
[14] Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated datamining platform[J]. Neoplasia, 2004, 6(1): 1-6.
[15] Dou XL, Bai CM. Cancer biomarkers and personalized cancer medicine[J]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 2015, 37(1): 113-117. DOI:10.3881/j.issn.1000-503X.2015.01.021.
[16] Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med, 2009, 361(10): 947-957.
[17] Incorvati JA, Shah S, Mu Y, et al. Targeted therapy for HER2 positive breast cancer[J]. J Hematol Oncol, 2013, 6(1): 23731980. DOI:10.1186/1756-8722-6-38.
[18] Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer[J]. Clin Chem, 2015, 61(1): 112-123. DOI:10.1373/clinchem.2014.222679.
[19] Cappelletti V, Appierto V, Tiberio P, et al. Circulating biomarkers for prediction of treatment response[J]. J Natl Cancer Inst Monogr, 2015 (51): 60-63. DOI:10.1093/jncimonographs/lgv006.
[20] Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early and latestage human malignancies[J]. Sci Transl Med, 2014, 6(224): 224ra24. DOI:10.1126/scitranslmed.3007094.
[21] Kim K. Big data key to improving health care[R]. AAMC Reporter, 2014, January.
[22] Taitsman JK, Grimm CM, Agrawal S. Protecting patient privacy and data security[J]. N Engl J Med, 2013, 368(11): 977-979. DOI:10.1056/NEJMp1215258.
[23] 李丹丹. 论个人医疗信息的法律保护[J]. 吉首大学学报: 社会科学版, 2015, 2(2): 87-93. DOI:10.13438/j.cnki.jdxb.2015.02.014.
[24] Huang J, Yu Y. Bioinformatics of tumor molecular targets from big data[J]. Zhonghua Wei Chang Wai Ke Za Zhi, 2015, 18(1): 9-12.
[25] Alyass A, Turcotte M, Meyre D. From big data analysis to personalized medicine for all: challenges and opportunities[J]. BMC Med Genomics, 2015, 8(1): 33. DOI:10.1186/s12920-015-0108-y. |